Investor Alert

Teva Pharmaceutical Industries Ltd. ADR



After Hours

 --Quotes are delayed by 20 min

Sep 29, 2023, 7:58 p.m.





+0.09 +0.88%


Volume 114,096

Quotes are delayed by 20 min


Previous close

$ 10.22

$ 10.20


-0.02 -0.20%

Day low

Day high




52 week low

52 week high




Annual Financials for Teva Pharmaceutical Industries Ltd. ADR

Fiscal year is January-December. All values ILS millions. 20182019202020212022 5-year trend
Sales/Revenue 65.69B60.12B57.29B51.19B50.11B
Cost of Goods Sold (COGS) incl. D&A 35.86B33.32B30.72B27.08B26.72B
COGS excluding D&A 29.24B27.18B25.37B22.78B22.32B
Depreciation & Amortization Expense 6.62B6.14B5.35B4.3B4.39B
Depreciation 2.43B2.17B1.85B1.71B1.94B
Amortization of Intangibles 4.19B3.97B3.51B2.59B2.46B
Gross Income 29.83B26.8B26.57B24.11B23.39B
20182019202020212022 5-year trend
SG&A Expense 19.51B17.16B16.05B14.2B14.39B
Research & Development 4.36B3.6B3.43B3.12B2.82B
Other SG&A 15.15B13.56B12.62B11.08B11.57B
Other Operating Expense -----
Unusual Expense 16.96B11.1B23.29B4.35B16.13B
EBIT after Unusual Expense (16.96B)(1.46B)(12.78B)5.56B(7.13B)
Non Operating Income/Expense 553.67M213.78M137.56M(187.35M)208.32M
Non-Operating Interest Income 140.22M146.08M82.54M--
Equity in Affiliates (Pretax) -----
Interest Expense 3.38B3.41B2.6B3.25B3.37B
Gross Interest Expense 3.38B3.41B2.6B3.25B3.37B
Interest Capitalized -----
Pretax Income (9.33B)(4.51B)(15.15B)2.13B(10.3B)
Income Tax (701.08M)(990.52M)(577.76M)681.56M(2.14B)
Income Tax - Current Domestic 2.52B3.15B625.9M872.13M1.44B
Income Tax - Current Foreign -----
Income Tax - Deferred Domestic (3.22B)(4.14B)(1.2B)(190.58M)(3.59B)
Income Tax - Deferred Foreign -----
Income Tax Credits -----
Equity in Affiliates (255.26M)(46.32M)474.59M29.07M70.56M
Other After Tax Income (Expense) -----
Consolidated Net Income (8.89B)(3.56B)(14.1B)1.47B(8.08B)
Minority Interest Expense (1.16B)(3.56M)(378.29M)125.97M(178.08M)
Net Income (7.73B)(3.56B)(13.72B)1.35B(7.91B)
Extraordinaries & Discontinued Operations -----
Extra Items & Gain/Loss Sale Of Assets -----
Cumulative Effect - Accounting Chg -----
Discontinued Operations -----
Net Income After Extraordinaries (7.73B)(3.56B)(13.72B)1.35B(7.91B)
Preferred Dividends 895.22M----
Net Income Available to Common (8.63B)(3.56B)(13.72B)1.35B(7.91B)
EPS (Basic) (8.45)(3.26)(12.53)1.22(7.12)
Basic Shares Outstanding 1.02B1.09B1.1B1.1B1.11B
EPS (Diluted) (8.45)(3.26)(12.53)1.22(7.12)
Diluted Shares Outstanding 1.02B1.09B1.1B1.11B1.11B
EBITDA 16.94B15.78B15.87B14.21B13.4B
Link to MarketWatch's Slice.